Highlights of This Issue 1345

SPECIAL FEATURES

1347 Editors’ Note

Introducing New Strategies in… James L. Abbruzzese, Alexander M.M. Eggermont, and Eric H. Rubin

CCR New Strategies

1348 New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance Brian I. Rini

CCR Translations

1355 Does Lapatinib Work against HER2-negative Breast Cancers? Ingrid A. Mayer and Carlos L. Arteaga

See article p. 1486

Statistics in Clinical Cancer Research

1358 Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge Irina Ostrovnaya and Colin B. Begg

CCR Drug Updates

1368 Everolimus Peter J. Houghton

Molecular Pathways

1373 HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy Marcia R. Campbell, Dhara Amin, and Mark M. Moasser

1384 Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward David G. Menter, Richard L. Schilsky, and Raymond N. DuBois

HUMAN CANCER BIOLOGY

1391 High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease–Related Small Bowel Adenocarcinomas Begoña Diosdado, Tineke E. Buffart, Russell Watkins, Beatriz Carvalho, Bauke Ylstra, Marianne Tijssen, Anne S. Boliijn, Fraser Lewis, Karen Maude, Caroline Verbeke, Iris D. Nagtegaal, Heike Grabsch, Chris J.J. Mulder, Phil Quirke, Peter Howdle, and Gerrit A. Meijer

1402 Critical Role of Gα13 and Gα13 for Human Small Cell Lung Cancer Cell Proliferation In vitro and Tumor Growth In vivo Marius Grzelinski, Olaf Pinkenburg, Thomas Büch, Maike Gold, Stefanie Stohr, Hermann Kalwa, Thomas Gudermann, and Achim Aigner

1416 Association of TGF-β1 Genetic Variants with HPV16-positive Oropharyngeal Cancer Xiaoxiang Guan, Erich M. Sturgis, Dapeng Lei, Zhensheng Liu, Kristina R. Dahlstrom, Qingyi Wei, and Guojun Li

1423 ZIP4 Regulates Pancreatic Cancer Cell Growth by Activating IL-6/STAT3 Pathway through Zinc Finger Transcription Factor CREB Yuqing Zhang, Uddalak Bharadwaj, Craig D. Logsdon, Changyi Chen, Qizhi Yao, and Min Li

1431 Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2 Jürgen Becker, Helena Pavlakovic, Fabian Ludewig, Fabiola Wilting, Herbert A. Weich, Romulo Albuquerque, Jayakrishna Ambati, and Jörg Wilting
CANCER THERAPY: PRECLINICAL

1442 Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevin Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wán L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang

1452 Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer
Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann

1466 An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity
Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong-Wan Kim, Wenle Xia, Neil Spector, Jeffrey Marks, William Barry, Amy Hobeika, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, and Tim Hoffman

1478 Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur

1486 Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance

1498 Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase 1 Evaluation
Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail

IMAGING, DIAGNOSIS, PROGNOSIS

1509 Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safra, Marlena S. Feijo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

1520 Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
Toshihiko Ishii, Takashi Ishida, Atae Utsumomiya, Atsushi Inagaki, Hiroki Yano, Hirokazu Komatsu, Shinsuke Iida, Kazunori Imada, Takashi Uchiyama, Shiro Akinaga, Kenya Shitara, and Ryuzo Ueda

1532 Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
Kateen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Egert, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavarrino, John M. Maris, Jaime Mora, Akira Nakagawara, André Obertshuer, Miki Ohtera, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandesompele

1542 Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers

1553 Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer
Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fisch, Tim Henrik Bruhmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuer, Markus Graeven, Hartwig Huland, Guido Sauter, and Thorsten Schlomm
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1587</td>
<td>Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab</td>
<td>Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi</td>
</tr>
<tr>
<td>1597</td>
<td>IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendrogial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group</td>
<td>Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Coes C. Tijsen, Denis Lacombe, Ahmed Idilbi, Ronald van Marion, Johan M. Kros, Winand N.M. Djinjens, Thierry Gorlia, and Marc Sanson</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1605</td>
<td>Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial</td>
<td>Nigel J. Bundred, Angela Cramer, Julie Morris, Lorna Renshaw, Kwok-Leung Cheung, Pamela Flint, Rachael Johnson, Oliver Young, Göran Landberg, Sue Grassby, Lorraine Turner, Andrew Baildam, Lester Barr, and J. Michael Dixon</td>
</tr>
<tr>
<td>1624</td>
<td>Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer</td>
<td>Josefine Becker, Lambert Skoog, Tommy Fomander, Bo Nordenskjöld, and Olle Stål</td>
</tr>
<tr>
<td>1634</td>
<td>A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma</td>
<td>Hui Huang, Michael Meneffee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo</td>
</tr>
<tr>
<td>1642</td>
<td>Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes</td>
<td>Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Keskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz</td>
</tr>
</tbody>
</table>
Clinical Cancer Research

LETERS TO THE EDITOR

Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Letter
Patrick Walsh

Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Response
Joseph Presti, Jr.

CORRECTIONS

Correction: PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
1692

Correction: MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival
1692

SUSCEPTIBILITY AND PREVENTION

Implications of LINE1 Methylation for Bladder Cancer Risk in Women

1682

ABOUT THE COVER

The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.